2024-04-162024-04-162024-03-21https://hdl.handle.net/20.500.12503/32603Purpose: Glioblastoma multiforme (GBM) stands as the most common form of primary brain cancer among adults, it has a five-year survival rate of 5% - 10%. Traditional treatment options include surgical intervention, chemotherapy, and radiation therapy. Recently, immunotherapy has emerged as a promising treatment paradigm for cancer. These immunotherapies often rely on targeting molecular antigens unique to cancer cells. Surface antigens such as CD155 (PVR), previously thought to be expressed almost exclusively by stem cells, can also be expressed on the surface of certain cancer cells. CD-155, in the context of cancer survival, acts to downregulate cancer killing mechanisms of Natural Killer (NK) cells, making it a promising target for immunotherapy. To treat GBM tumors lacking expression of established antigens, our laboratory has embarked on the quest to uncover novel antigens specific to GBM, envisioned as candidates for Natural Killer (NK) cell-mediated immunotherapy. Methods: This experiment investigated the potential expression of cell surface CD155 on the LN-18 glioblastoma cell line utilizing flow cytometry, employing PE-labeled antibodies designed for CD155 detection. To ensure accuracy, we employed two negative control groups for this cell line: 1) unstained LN-18 cells and 2) LN-18 cells stained with PE-mIgG2a isotype control antibodies. Our hypothesis posited that LN-18 cells would exhibit a heightened fluorescence signal from anti-CD155 antibodies compared to the fluorescence levels observed in the negative control groups (unstained and isotype control-stained cells). Results and Conclusions: Based on the detection of increased fluorescence signal versus negative controls, CD155 was identified to be expressed on LN-18 cells.enposter